NK510 Cell Therapy for Active Lupus Not Controlled by Standard Treatments
Part of Immune system & allergy, Skin clinical trials.
This study tests a new treatment called NK510, which uses your own immune cells (natural killer cells) to calm down the overactive immune system in lupus. It is for people with lupus that is not controlled by standard treatments like steroids and other medicines.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have been diagnosed with Systemic Lupus Erythematosus (SLE) using standard criteria.
- Your lupus is still active despite trying standard treatments (like steroids and other lupus medicines) for at least 2 months.
- You have a certain level of lupus disease activity (SLEDAI-2K score > 8) and a positive antinuclear antibody (ANA) test.
- Your blood counts and organ functions (liver, kidneys) are within acceptable ranges.
- You do not have active lupus nephritis (kidney inflammation), serious infections, or other major health issues that would make the study unsafe.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether combining immune cells (NK cells) with rituximab can help people with hard-to-treat lupus or lupus-related kidney disease. It is for patients whose lupus is still active despite standard treatments.
This study tests a new type of immune cell therapy (CAR-T cells) designed to target and reduce the immune cells driving lupus in patients whose disease hasn't responded to standard treatments. Researchers will first identify which specific immune cells are causing your lupus, then engineer your own immune cells to fight them.
This study tests a new therapy called NKX019, which uses specially engineered natural killer cells to target a protein on lupus cells. It is for people with moderate to severe lupus that has not responded to standard treatments, especially those with active kidney inflammation.
This trial tests a new immune cell therapy (CAR NK cells) for people with moderate to severe lupus that hasn't responded well to standard treatments. The therapy targets a protein called CD19 on certain immune cells to calm the overactive immune system.
This trial tests a new treatment called KN5501 (a type of cell therapy) for people with lupus that hasn't been controlled by usual medicines. It aims to see if this treatment can help calm the immune system and reduce lupus activity.
This is an early-stage trial testing a new type of immune cell therapy (called ES-NK cells) for people with difficult-to-treat lupus nephritis—kidney inflammation caused by lupus. The goal is to see if this treatment is safe and can help calm the disease when standard medicines aren't working well enough.
Hear when a new Refractory Systemic Lupus Erythematosus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.